Bluejay Diagnostics Inc(BJDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BJDX Bluejay Diagnostics Inc

Trading 03-20 13:23:02 EDT

1.85

-0.07

-3.87%

High1.94	Low1.79	Vol7.29K
Open1.79	D1 Closing1.92	Amplitude7.57%
Mkt Cap1.79M	Tradable Cap1.56M	Total Shares972.00K
T/O13.71K	T/O Rate0.86%	Tradable Shares844.20K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BJDX","market":"US","secType":"STK","nameCN":"Bluejay Diagnostics Inc","latestPrice":1.8457,"timestamp":1774027258604,"preClose":1.92,"halted":0,"volume":7285,"delay":0,"changeRate":-0.038697916666666686,"floatShares":844200,"shares":972000,"eps":-15.251285,"marketStatus":"Trading","change":-0.0743,"latestTime":"03-20 13:23:02 EDT","open":1.7946,"high":1.94,"low":1.7946,"amount":13711.0948575,"amplitude":0.075729,"askPrice":1.93,"askSize":57,"bidPrice":1.81,"bidSize":292,"shortable":3,"etf":0,"ttmEps":-15.251285,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1636520400000,"exchange":"NASDAQ","adjPreClose":1.92,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.92,"latestTime":"08:35 EDT","volume":4,"amount":7.34,"timestamp":1774010107329,"change":-0.17,"changeRate":-0.088542,"amplitude":0.088542},"postHourTrading":{"tag":"盘后","latestPrice":1.8562,"preClose":1.95,"latestTime":"19:50 EDT","volume":321,"amount":604.71,"timestamp":1773964251770,"change":-0.0938,"changeRate":-0.048103,"amplitude":0.048103},"volumeRatio":0.779752},"requestUrl":"/m/hq/s/BJDX/wiki","defaultTab":"wiki","newsList":[{"id":"2620405277","title":"Bluejay Diagnostics sells 62,500 shares in private placement for USD 125,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405277","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405277?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:30","pubTimestamp":1773783051,"startTime":"0","endTime":"0","summary":"Bluejay Diagnostics entered into a securities purchase agreement on March 14, 2024 to sell 62,500 shares of common stock at USD 2 per share. The private placement closed on March 17, 2026 for gross proceeds of USD 125,000. The purchasers were board members Neil Dey, Donald Chase, Svetlana Dey, Douglas Wurth and Fred Zeidman. The shares were sold in an unregistered private placement under Section 4 of the Securities Act and/or Rule 506 of Regulation D.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9yKr8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BJDX","BK4082"],"gpt_icon":0},{"id":"2618339951","title":"Bluejay Diagnostics’ Symphony IL-6 sepsis study accepted for SAEM annual meeting presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618339951","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618339951?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:30","pubTimestamp":1773311425,"startTime":"0","endTime":"0","summary":"Bluejay will attend the Society of Academic Emergency Medicine Annual Meeting on May 18-21, 2026, in Atlanta, Georgia. The company’s Symphony IL-6 Test abstract is scheduled for presentation during the meeting. Presenters listed are John Lee and Nathan Shapiro.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2Tz13f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4082","IE00BKPKM429.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD","BK4588","BK4585","SG9999014021.USD","SG9999014039.USD","NDAQ","BJDX","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2618292810","title":"NorthStrive Fund urges Bluejay to evaluate strategic opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2618292810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618292810?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:35","pubTimestamp":1773236111,"startTime":"0","endTime":"0","summary":"NorthStrive Fund II issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics (BJDX), recommending the Board evaluate...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/northstrive-fund-urges-bluejay-to-evaluate-strategic-opportunity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/northstrive-fund-urges-bluejay-to-evaluate-strategic-opportunity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2618928572","title":"Northstrive Fund Ii: Recommending Bluejay Board Evaluates a Strategic Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928572","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618928572?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:30","pubTimestamp":1773235807,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0GG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2618285579","title":"Northstrive Fund Ii:Letter Recommend Bluejay Board Review Potential Acquisition of Phase-1-Ready Therapeutic Asset Targeting Refractory Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2618285579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618285579?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:30","pubTimestamp":1773235807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0GG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2618283929","title":"Northstrive Fund Ii Lp Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2618283929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618283929?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:30","pubTimestamp":1773235807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BJDX","BK4082"],"gpt_icon":0},{"id":"2617630006","title":"Bluejay Diagnostics FY2025 net loss narrows 11% to $6.85 million as interest expense plunges 100% to $0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617630006","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617630006?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:03","pubTimestamp":1772830995,"startTime":"0","endTime":"0","summary":"Bluejay Diagnostics Inc. reported a 2025 net loss of 6.85 million, narrowing 11% year over year. Research and development expense fell 12% to 3.05 million, while general and administrative expense rose 6% to 3.91 million. Net cash used in operating activities improved 23% to 6.05 million, and cash and cash equivalents were 5.16 million at year-end. Management said it expects cash resources to fund operations into the third quarter of 2026 and noted it will need additional capital to fund planned operations for the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL8fhBnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BJDX","BK4082"],"gpt_icon":0},{"id":"2617603635","title":"Bluejay Diagnostics Outlines 2026 Plans to Complete SYMON II Study, Advance Toward Regulatory Submission, Scale Manufacturing for Commercialization and Raise Additional Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617603635","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617603635?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:22","pubTimestamp":1772806949,"startTime":"0","endTime":"0","summary":"Bluejay Diagnostics Outlines 2026 Plans to Complete SYMON II Study, Advance Toward Regulatory Submission, Scale Manufacturing for Commercialization and Raise Additional Capital. Bluejay Diagnostics Inc. outlined plans through 2026 to complete and execute the SYMON II clinical study and advance toward a regulatory submission for its Symphony platform IL-6 test. The company also plans to continue manufacturing scale-up and operational preparations for commercialization, strengthen supply-chain robustness and production capacity, and further develop Symphony platform capabilities. Bluejay said it will continue engagement with investors, conferences, and potential strategic partners, and expects to raise at least $20 million in additional capital through the end of fiscal year 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDLbvMLF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2617768233","title":"Bluejay Diagnostics Inc - Will Need to Raise at Least $20 Mln of Further Capital Through End of FY2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2617768233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617768233?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:30","pubTimestamp":1772796600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA5B6F3S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2617682393","title":"Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682393","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617682393?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:30","pubTimestamp":1772796600,"startTime":"0","endTime":"0","summary":"ACTON, Mass., March  06, 2026  (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/06/3250942/0/en/Bluejay-Diagnostics-Provides-Corporate-Update-and-2026-Strategic-Outlook.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2612026968","title":"Bluejay Diagnostics Says All Prefunded Warrants Have Been Exercised","url":"https://stock-news.laohu8.com/highlight/detail?id=2612026968","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612026968?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:30","pubTimestamp":1771587019,"startTime":"0","endTime":"0","summary":"Bluejay Diagnostics said all prefunded warrants from its October 2025 private placement were fully exercised as of Feb. 19, 2026, leaving no prefunded warrants outstanding. The company now has about 972,000 common shares outstanding and said it still has cash-exercisable warrants outstanding for roughly 1.5 million shares with exercise prices of $7.00 or higher.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL67jRfL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4082","BK4112","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BJDX"],"gpt_icon":0},{"id":"2612841060","title":"Bluejay Advances SYMON II Sepsis Study and Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612841060","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612841060?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:37","pubTimestamp":1771414631,"startTime":"0","endTime":"0","summary":"Bluejay Diagnostics ( ($BJDX) ) has shared an update. On February 17, 2026, Bluejay Diagnostics reported significant progress in its SYMON II multi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bluejay-advances-symon-ii-sepsis-study-and-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bluejay-advances-symon-ii-sepsis-study-and-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2612843459","title":"Bluejay Diagnostics Enrolls 545 Patients in SYMON II Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2612843459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612843459?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:30","pubTimestamp":1771327835,"startTime":"0","endTime":"0","summary":"Bluejay Diagnostics Inc. announced the successful enrollment of 545 patients in its SYMON II multicenter clinical study, targeting a total of 750 patients. The company is advancing manufacturing readiness and technology transfer initiatives into 2026 in preparation for FDA submission and future commercialization. Results from the SYMON II study have not yet been presented, as the company is transitioning from clinical enrollment to data analysis and regulatory engagement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL8WmjQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","BK4112","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","BK4082","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014005.SGD","BJDX","SG9999014039.USD","NDAQ","BK4585"],"gpt_icon":0},{"id":"2612459820","title":"Bluejay Diagnostics Successfully Enrolls 545 Patients in Symon™ Ii Study and Advances Manufacturing Readiness Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612459820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612459820?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:30","pubTimestamp":1771327800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA3MTDQ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BJDX","BK4082"],"gpt_icon":0},{"id":"2607727915","title":"Bluejay Diagnostics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2607727915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607727915?lang=en_us&edition=fundamental","pubTime":"2026-01-29 08:50","pubTimestamp":1769647810,"startTime":"0","endTime":"0","summary":"19:50 EST Bluejay Diagnostics (BJDX) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluejay-diagnostics-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluejay-diagnostics-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2607727898","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2607727898","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607727898?lang=en_us&edition=fundamental","pubTime":"2026-01-29 08:50","pubTimestamp":1769647800,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nAQN2LJLU7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2606078285","title":"Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2606078285","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606078285?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"ACTON, Mass., Jan.  27, 2026  (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226438/0/en/Bluejay-Diagnostics-Announces-1-for-4-Reverse-Stock-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BJDX","BK4082"],"gpt_icon":0},{"id":"2606424896","title":"Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2606424896","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606424896?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432454,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus  to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL3typFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BJDX","MIRM","BK4082"],"gpt_icon":0},{"id":"2595787326","title":"Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787326","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787326?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:00","pubTimestamp":1767009600,"startTime":"0","endTime":"0","summary":"ACTON, Mass., Dec.  29, 2025  (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/29/3210856/0/en/Bluejay-Diagnostics-Announces-Completion-of-Commercial-Scale-IL-6-Antibody-Production.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BJDX"],"gpt_icon":0},{"id":"2582385808","title":"Bluejay Diagnostics Reports Q3 Results and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582385808","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582385808?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:48","pubTimestamp":1762811318,"startTime":"0","endTime":"0","summary":"An update from Bluejay Diagnostics ( ($BJDX) ) is now available. On November 10, 2025, Bluejay Diagnostics announced its third-quarter financial re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bluejay-diagnostics-reports-q3-results-and-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bluejay-diagnostics-reports-q3-results-and-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BJDX","BK4082"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bluejaydx.com","stockEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":-0.2751},{"period":"3month","weight":-0.3906},{"period":"6month","weight":-0.6661},{"period":"1year","weight":-0.8811},{"period":"ytd","weight":-0.2693}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.09176},{"month":2,"riseRate":0.4,"avgChangeRate":-0.020494},{"month":3,"riseRate":0.4,"avgChangeRate":-0.09359},{"month":4,"riseRate":0.25,"avgChangeRate":-0.27562},{"month":5,"riseRate":0.25,"avgChangeRate":-0.095203},{"month":6,"riseRate":0.5,"avgChangeRate":-0.162527},{"month":7,"riseRate":0.5,"avgChangeRate":-0.039437},{"month":8,"riseRate":0,"avgChangeRate":-0.219139},{"month":9,"riseRate":0.25,"avgChangeRate":-0.176769},{"month":10,"riseRate":0.5,"avgChangeRate":-0.040237},{"month":11,"riseRate":0,"avgChangeRate":-0.194266},{"month":12,"riseRate":0.2,"avgChangeRate":-0.253394}],"exchange":"NASDAQ","name":"Bluejay Diagnostics Inc","nameEN":"Bluejay Diagnostics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bluejay Diagnostics Inc(BJDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bluejay Diagnostics Inc(BJDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bluejay Diagnostics Inc,BJDX,Bluejay Diagnostics Inc股票,Bluejay Diagnostics Inc股票老虎,Bluejay Diagnostics Inc股票老虎国际,Bluejay Diagnostics Inc行情,Bluejay Diagnostics Inc股票行情,Bluejay Diagnostics Inc股价,Bluejay Diagnostics Inc股市,Bluejay Diagnostics Inc股票价格,Bluejay Diagnostics Inc股票交易,Bluejay Diagnostics Inc股票购买,Bluejay Diagnostics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bluejay Diagnostics Inc(BJDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bluejay Diagnostics Inc(BJDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction